Johnson & Johnson (JNJ) Reports Promising Phase 1/1b Results in Advanced Lung Cancer

Johnson & Johnson (JNJ) on May 30, 2026, announced its investigational therapy for advanced non-small cell lung cancer showed encouraging efficacy in a Phase 1/1b study. The data could support advancing the drug into late-stage testing. The trial met its primary endpoints, demonstrating a manageable safety profile and a clinically meaningful overall response rate in patients who had exhausted standard treatments, the company said. J&J withheld specific figures but plans to present detailed results at a future medical conference. The update reinforces J&J’s pipeline growth as it faces patent expirations on older drugs. The lung cancer market, dominated by Merck’s Keytruda and AstraZeneca’s Tagrisso, is a strategic priority. JNJ shares were little changed in premarket trading.